Sang Jun Han

Title: Innovations of Sang Jun Han in Cancer Treatment

Introduction

Sang Jun Han is a notable inventor based in Houston, Texas, recognized for his contributions to cancer treatment through innovative methodologies. He holds three patents that focus on the targeting of SRC-3 in immune cells, particularly T regulatory cells, as a therapeutic approach for cancer.

Latest Patents

His latest patents include methods and compositions related to cancer treatment that involve targeting SRC-3 in immune cells. This approach is particularly effective in eradicating tumors in mammals. In specific cases, T regulatory cells are subjected to CRISPR ex vivo to produce cells suitable for adoptive cell transfer. Additionally, one or more agents that target SRC-3 may be administered to the individual or exposed to the cells prior to administration.

Career Highlights

Sang Jun Han is affiliated with Baylor College of Medicine, where he continues to advance research in immunomodulatory therapies for cancer. His work has significant implications for the development of new treatment strategies that harness the body's immune system to combat cancer.

Collaborations

Some of his notable coworkers include Bert W O'Malley and David Michael Lonard, who contribute to the collaborative research efforts in the field of cancer treatment.

Conclusion

Sang Jun Han's innovative work in targeting SRC-3 in immune cells represents a promising advancement in cancer therapy. His contributions are paving the way for new treatment options that could significantly improve patient outcomes.